GD-DICLOFENAC/MISOPROSTOL 50 200 MCG
MISOPROSTOL : 200 MCG DICLOFENAC SODIUM : 50 MG · DIN 02341689 · GENMED A DIVISION OF PFIZER CANADA ULC
Health Canada status: MARKETED
What is GD-DICLOFENAC/MISOPROSTOL 50?
GD-DICLOFENAC/MISOPROSTOL 50 200 MCG contains MISOPROSTOL : 200 MCG DICLOFENAC SODIUM : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02341689, held by GENMED A DIVISION OF PFIZER CANADA ULC, supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Jul-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02341689 |
|---|---|
| Brand name | GD-DICLOFENAC/MISOPROSTOL 50 |
| Generic / active ingredient | MISOPROSTOL : 200 MCG DICLOFENAC SODIUM : 50 MG |
| Manufacturer | GENMED A DIVISION OF PFIZER CANADA ULC |
| Strength | 200 MCG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB55 DICLOFENAC, COMBINATIONS |
| AHFS class | 28:08.04.92 ; 56:28.28 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Jul-2014 |
| Original market date | 2014-07-22 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M01AB55 DICLOFENAC, COMBINATIONS. 6 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARTHROTEC 50 | 50 MG | TABLET (DELAYED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 01917056 |
| ARTHROTEC 75 | 200 MCG | TABLET (DELAYED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02229837 |
| GD-DICLOFENAC/MISOPROSTOL 75 | 200 MCG | TABLET (DELAYED-RELEASE) | GENMED A DIVISION OF PFIZER CANADA ULC | MARKETED | DIN 02341697 |
| PMS-DICLOFENAC-MISOPROSTOL | 50 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02413469 |
| PMS-DICLOFENAC-MISOPROSTOL | 75 MG | TABLET (DELAYED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02413477 |
| ACT DICLO-MISO | 50 MG | TABLET (ENTERIC-COATED) | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02397145 |
| ACT DICLO-MISO | 75 MG | TABLET (ENTERIC-COATED) | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02397153 |
| DICLOFENAC MISOPROSTOL | 200 MCG | TABLET (ENTERIC-COATED) | ABRI PHARMACEUTICALS INC | CANCELLED PRE MARKET | DIN 02405474 |
| DICLOFENAC MISOPROSTOL | 75 MG | TABLET (ENTERIC-COATED) | ABRI PHARMACEUTICALS INC | CANCELLED PRE MARKET | DIN 02405482 |
| SANDOZ DICLOFENAC MISOPROSTOL | 50 MG | TABLET | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02400596 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.